Matinas BioPharma (MTNB) Stock Statistics & Valuation Metrics

Matinas BioPharma has a market cap or net worth of $3.20M. The enterprise value is $10.06M.

Matinas BioPharma has 5,086,985 shares outstanding. The number of shares has decreased by -2.65% in one year.

Matinas BioPharma’s return on equity (ROE) is -1.19 and return on invested capital (ROIC) is -102.69%.

The current PE Ratio of Matinas BioPharma is -2.05. Matinas BioPharma’s PEG ratio is -0.03.

In the last 12 months, Matinas BioPharma had revenue of 1.10M and earned -22.94M in profits. Earnings per share was -5.28.

In the last 12 months, operating cash flow was -16.95M and capital expenditures 0.00, giving a free cash flow of -16.95M billion.

Matinas BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―

Matinas BioPharma upcoming earnings date is May 8, 2025, TBA Not Confirmed.

Matinas BioPharma as a current ratio of 5.93, with Debt / Equity ratio of 19.46%

In the past 12 months, Matinas BioPharma has paid 0.00 in taxes.

Matinas BioPharma EV to EBITDA ratio is -2.00, with an EV/FCF ratio of -2.95.

Matinas BioPharma has $10.79M in cash and marketable securities with $390.74K in debt, giving a net cash position of -$7.72M billion.

Gross margin is 165.78%, with operating margin of -2168.43%, and net profit margin of -2093.25%.

The average price target for Matinas BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is Hold